SUN-348 Cabozantinib in Advanced Adrenocortical Carcinoma: Rationale and Protocol of Two Phase II Clinical Trials

BACKGROUND: Median overall survival (OS) in advanced adrenocortical (ACC) is only 12-15 months. Mitotane and chemotherapy are the backbones of current treatment but prolonged disease stabilization is rare. Cabozantinib (CABO) is an oral multi-kinase inhibitor (MKI) of c-MET, VEGFR2, AXL, and RET. OB...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Endocr Soc
Autors principals: Kroiss, Matthias, Goebeler, Maria-Elisabeth, Jimenez, Camilo, Malzahn, Uwe, Fassnacht, Martin, Habra, Mouhammed
Format: Artigo
Idioma:Inglês
Publicat: Endocrine Society 2019
Matèries:
Adrenal
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6553301/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-348
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars